Inovio Pharmaceuticals (INO) Enterprise Value (2010 - 2026)

Inovio Pharmaceuticals has disclosed Enterprise Value across 17 years of filings, most recently posting $53.1 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 68.76% year-over-year to $53.1 million; the TTM figure through Jun 2026 stood at $53.1 million (up 68.76% YoY), while the FY2025 annual figure was $23.1 million, up 151.95% from the prior year.
• Enterprise Value came in at $53.1 million for Q2 2026 at Inovio Pharmaceuticals, down from $105.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $461.8 million in Q1 2022 to a low of -$75.2 million in Q2 2023.
• Average Enterprise Value over 5 years is $74.4 million, with a median of $59.6 million recorded in 2024.
• The largest YoY upside for Enterprise Value was 3155.81% in 2024 against a maximum downside of 665.65% in 2024.
• Over 5 years, Enterprise Value stood at $141.8 million in 2022, then sank by 104.09% to -$5.8 million in 2023, then sank by 665.65% to -$44.4 million in 2024, then surged by 151.95% to $23.1 million in 2025, then surged by 130.2% to $53.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $53.1 million in Q2 2026, $105.5 million in Q1 2026, and $23.1 million in Q4 2025.